BioNTech and InstaDeep to Host Second AI Day on October 1, 2025
ByAinvest
Tuesday, Sep 23, 2025 6:46 am ET1min read
BNTX--
The AI Day event will be accessible through a live webcast and will be available on BioNTech's Investor Relations website for one year following the event. The recording will be archived on the company's website for participants to review at their convenience. This event marks a significant milestone in BioNTech's continued focus on AI development, following their acquisition of InstaDeep Ltd. [1]
BioNTech's AI strategy is aimed at leveraging artificial intelligence to accelerate the development of novel biopharmaceuticals. The company's portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. By integrating AI into its research and development processes, BioNTech aims to enhance the efficiency and effectiveness of its pipeline.
The event will provide an overview of BioNTech’s AI strategy and capabilities, as well as the application of AI in the company's pipeline and internal processes. The live webcast of the event will be available via this link. Participants may also access the slides and a recording of the event via the “Events & Presentations” page in the Investor Relations section of BioNTech’s website at . The recording will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year thereafter.
BioNTech, a global immunotherapy company, will host its second AI Day on October 1, 2025, in London. The event will showcase the company's AI strategy and capabilities, as well as its application in the pipeline and internal processes. The live webcast will be available on BioNTech's website, and the recording will be archived for one year. The event is part of the company's Innovation Series.
BioNTech SE (NASDAQ: BNTX), a global biopharmaceutical company specializing in immunotherapy, has announced its second AI Day event as part of its Innovation Series. The event is scheduled for October 1, 2025, at 9:00 AM EDT in London. This event will provide insights into BioNTech's AI strategy and its applications in the company's pipeline and internal processes.The AI Day event will be accessible through a live webcast and will be available on BioNTech's Investor Relations website for one year following the event. The recording will be archived on the company's website for participants to review at their convenience. This event marks a significant milestone in BioNTech's continued focus on AI development, following their acquisition of InstaDeep Ltd. [1]
BioNTech's AI strategy is aimed at leveraging artificial intelligence to accelerate the development of novel biopharmaceuticals. The company's portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. By integrating AI into its research and development processes, BioNTech aims to enhance the efficiency and effectiveness of its pipeline.
The event will provide an overview of BioNTech’s AI strategy and capabilities, as well as the application of AI in the company's pipeline and internal processes. The live webcast of the event will be available via this link. Participants may also access the slides and a recording of the event via the “Events & Presentations” page in the Investor Relations section of BioNTech’s website at . The recording will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year thereafter.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet